Ísrael - hebreska - Ministry of Health

sanofi - aventis israel ltd - oxaliplatin 5 mg/ml - concentrate for solution for infusion - oxaliplatin - in combination with 5- fluorouracil and folinic acid (fa), oxaliplatin is indicated for: - adjuvant treatment of stage iii ( duke's c) colon cancer after complete resection of primary tumour - the treatment of metastatic colorectal cancer.

Ísrael - hebreska - Ministry of Health

sanofi - aventis israel ltd - oxaliplatin 5 mg/ml - concentrate for solution for infusion - oxaliplatin - in combination with 5- fluorouracil and folinic acid (fa), oxaliplatin is indicated for: - adjuvant treatment of stage iii ( duke's c) colon cancer after complete resection of primary tumour - the treatment of metastatic colorectal cancer.

Ísrael - hebreska - Ministry of Health

salomon,levin & elstein ltd - oxaliplatin 5 mg/ml - concentrate for solution for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil (5-fu) and folinic acid (fa) is indicated for : - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour. - treatment of metastatic colorectal cancer.

Ísrael - hebreska - Ministry of Health

novapharma ltd - oxaliplatin 5 mg/ml - concentrate for solution for infusion - oxaliplatin - in combination with 5- fluorouracil and folinic acid (fa) oxaliplatin is indicated for: - adjuvant treatment of stage iii ( duke's c) colon cancer after complete resection of primary tumour - the treatment of metastatic colorectal cancer.

Ísrael - hebreska - Ministry of Health

medison pharma ltd - oxaliplatin 5 mg/ml - concentrate for solution for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil and folinic acid (fa), oxaliplatin is indicated for: - adjuvant treatment of stage iii ( duke's c) colon cancer after complete resection of primary tumour - the treatment of metastatic colorectal cancer.

Ísrael - hebreska - Ministry of Health

neopharm scientific ltd - catumaxomab 100 mcg/ml - concentrate for solution for infusion - catumaxomab - intraperitoneal treatment of malignant ascites in patients with epcam-positive carcinomas where standard therapy is not available or no longer feasible.

Ísrael - hebreska - Ministry of Health

glaxo smith kline (israel) ltd - ofatumumab 20 mg/ml - concentrate for solution for infusion - ofatumumab - treatment of chronic lymphocytic leukaemia (cll) in patients who are refractory to fludarabine and alemtuzumab

Ísrael - hebreska - Ministry of Health

glaxo smith kline (israel) ltd - ofatumumab 20 mg/ml - concentrate for solution for infusion - ofatumumab - treatment of chronic lymphocytic leukaemia (cll) in patients who are refractory to fludarabine and alemtuzumab

Ísrael - hebreska - Ministry of Health

novapharma ltd - irinotecan (trihydrate) hydrochloride 20 mg/ml - concentrate for solution for infusion - irinotecan - irinotecan is indicated for the treatment of patients with metastatic colorectal cancer: - in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. - as a single agent in patients who have failed an astablished 5-fluorouracil containing treatment regimen. for the treatment of patients with small cell lung cancer. for the treatment of patients with gastric cancer.

Ísrael - hebreska - Ministry of Health

salomon,levin & elstein ltd - irinotecan hydrochloride trihydrate 20 mg / 1 ml - concentrate for solution for infusion - irinotecan - irinotecan is indicated for the treatment of patients with metastatic colorectal cancer: - in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. - as a single agent in patients who have failed an astablished 5-fluorouracil containing treatment regimen. for the treatment of patients with small cell lung cancer. for the treatment of patients with gastric cancer.